Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Isaac Yang

Brain & Spinal Tumor · UCLA

View

Dr. Rohan Ramakrishna

Brain & Spinal Tumor · WCM

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Richard Dutton

General Anesthesiology · UMSOM

View

Dr. Sarah Ro

Obesity Medicine · UNC Health Care

View

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. Jed Wolpaw

General Anesthesiology · Johns Hopkins

View

Dr. Matt Sherrer

Perioperative Med · UAB

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    68GA DOTATATE PET in Schwannomas: Distinct Avidity Pattern Supporting Noninvasive Diagnosis.

    Jul 1, 2026DOI: 10.3174/ajnr.a9183Journal ArticleAJNR

    Written by: Sara LuckNeil SathiHiba ShaqraAli MozayanArsalan HaghdelBenjamin LiechtyJoseph R OsborneSara StraussJoshua D PalmerPhilip StiegJana Ivanidze

    Find these authors on Roon

    PS
    Dr. Philip Stieg
    Cerebrovascular Neurosurgery · NYP Weill Cornell

    Summary

    BACKGROUND AND PURPOSE: Schwannomas are a key diagnostic consideration in patients with enhancing extra-axial intracranial, skull base, and neck masses. While contrast-enhanced MRI is the diagnostic mainstay, its specificity can be limited, especially in small or atypical lesions. [68GA]DOTATATE PET/MRI and PET/CT, which target somatostatin receptor subtype 2 (SSTR2), represent an established tool in evaluating SSTR2-positive tumors, most notably meningiomas and paragangliomas, entities that can mimic schwannomas on conventional MRI. However, data on SSTR2 expression in schwannomas remain limited. We aimed to characterize [68GA]DOTATATE PET imaging features in patients with imaging-defined schwannomas.MATERIALS AND METHODS: We retrospectively identified patients who underwent [68GA]DOTATATE PET/MRI or PET/CT for evaluation of known or suspected SSTR2-positive tumors and had MRI features diagnostic of schwannoma. PET/CT or PET/MRI was performed as part of clinical evaluation according to previously published institutional protocols. Lesion maximum standardized uptake values (SUV), superior sagittal sinus (SSS) SUV (blood pool reference), and SUV ratios relative to the SSS (SUVRSSS) were measured.RESULTS: Sixteen patients met the inclusion criteria (mean age 62.1 ± 13.4 years; 43.8% women). The cohort included 6 patients with isolated schwannomas and 10 with concurrent meningiomas. None had prior radiotherapy. All lesions demonstrated minimal [68GA]DOTATATE avidity; the mean maximum lesion SUV was 1.6 ± 0.7, and the mean SUVRSSS was 1.5 ± 0.7, values well below established thresholds for meningioma diagnosis.CONCLUSIONS: Schwannomas exhibit minimal [68GA]DOTATATE avidity, in contrast to SSTR2-expressing tumors such as meningiomas. [68GA]DOTATATE PET may therefore aid in noninvasively differentiating schwannomas from SSTR2-expressing tumors with overlapping MRI features in diagnostically challenging cases.
    PSDr. Philip Stieg

    Dr. Philip Stieg

    Neurosurgery · Cerebrovascular Neurosurgery
    NewYork–Presbyterian Hospital
    philips